IntelGenx Technologies Corp. Announces Closing of Private Placement

SAINT LAURENT, QUEBEC, Jul 14 (MARKET WIRE) --
IntelGenx Technologies Corp. (the "Company") (TSX VENTURE: IGX)(OTCBB:
IGXT) announced today that it has closed a private placement offering of
approximately 10.5 million special warrants ("Special Warrants") at a
price of CDN$0.40 per Special Warrant for gross proceeds of approximately
CDN$4.2 million (the "Offering"). The Offering was made and the Special
Warrants were issued to investors in the Provinces of Ontario, British
Columbia, Alberta and Manitoba pursuant to exemptions from prospectus
requirements under applicable securities laws in the Provinces where the
offering was made, and from registration requirements in the United
States Securities Act of 1933, as amended (the "U.S. Securities Act").
Each Special Warrant entitles its holder to receive, upon exercise or
deemed exercise thereof, one common share of the Company (a "Unit Share")
and one common share purchase warrant (a "Warrant"). Each Warrant
entitles the holder thereof to purchase one Common Share ("Warrant
Share") at a price of US$0.80 until July 13, 2012. The proceeds of the
private placement will be used to support the Company's strategic
development projects and for working capital purposes.

Pursuant to an agency agreement entered into at closing, the Company
engaged Paradigm Capital Inc., Bolder Investment Partners Ltd. and Union
Securities Ltd. as agents (the "Agents") to complete the private
placement on a best efforts basis. The Company paid the Agents cash
compensation equal to 8% of the gross proceeds of the Offering, granted
Agents' compensation options ("Compensation Options") entitling the
Agents to purchase a number of common shares of the Company equal to 8%
of the number of Special Warrants sold in the Offering and issued a
number of common shares of the Company ("Broker Shares") to the Agents
equal to 4% of the number of Special Warrants sold in the Offering. Each
Compensation Option entitles the holder thereof to purchase one Common
Share ( "Compensation Option Share") at a price of US $0.80 until July
13, 2012.

The Special Warrants, the Unit Shares, the Warrants, the Warrant Shares,
the Compensation Options, the Compensation Option Shares and Broker
Shares are subject to statutory resale restrictions under applicable
securities laws in Canada until November 14, 2009, and they have not been
registered under the U.S. Securities Act and as such are "restricted
securities" within the meaning of Rule 144 under the U.S. Securities Act
and are subject to applicable resale restrictions thereunder.

Under the terms of the agency agreement, the Company has agreed to use
commercially reasonable efforts to, as soon as practicable following
closing, file and obtain a receipt for a final short form prospectus
("Prospectus") in the Provinces of Ontario, British Columbia, Alberta,
Manitoba and Quebec and to file a registration statement with and to have
it declared effective by the United States Securities & Exchange
Commission.

The Special Warrants shall be deemed exercised on behalf of, and without
any required action on the part of, the holder thereof on the earlier of:
(i) the fifth business day (the "Clearance Date") after the later of the
date the Corporation receives a receipt for the Prospectus qualifying the
distribution of the Unit Shares and Warrants issuable on the exercise of
the Special Warrants in the Qualifying Provinces and the date a
registration statement is declared effective by the United States
Securities & Exchange Commission; and (ii) 4 months and one day after
closing. In the event the Clearance Date does not occur on or prior to
120 days following the closing, each Special Warrant shall entitle the
holder thereof to 1.1 Unit Shares and 1.1 Warrants (in lieu of 1 Unit
Share and 1 Warrant) upon the deemed exercise of such Special Warrants.

The securities discussed herein have not been registered under the U.S.
Securities Act and may not be offered or sold absent registration under
the U.S. Securities Act or an applicable exemption from the registration
requirements thereof. This press release does not constitute an offer to
sell or a solicitation of an offer to buy, nor shall there be any sale of
these securities in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such jurisdiction or an exemption therefrom.

ABOUT INTELGENX:

IntelGenx is a drug delivery company focused on the development of oral
controlled-release products as well as novel rapidly disintegrating
delivery systems. IntelGenx uses its unique multiple layer delivery
system to provide zero-order release of active drugs in the
gastro-intestinal tract. IntelGenx has also developed novel delivery
technologies for the rapid delivery of pharmaceutically active substances
in the oral cavity based on its experience with rapidly disintegrating
films. IntelGenx's research and development pipeline includes products
for the treatment of pain, hypertension, osteoarthritis, and depressive
disorders. More information is available about the company at
www.intelgenx.com.

FORWARD LOOKING STATEMENTS:

This document may contain forward-looking information about IntelGenx's
operating results and business prospects that involve substantial risks
and uncertainties. Statements that are not purely historical are
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended, and Section 27A of the
Securities Act of 1933, as amended. These statements include, but are not
limited to, statements about IntelGenx's plans, objectives, expectations,
strategies, intentions or other characterizations of future events or
circumstances and are generally identified by the words "may," "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates,"
"could," "would," and similar expressions. All forward looking statements
are expressly qualified in their entirety by this cautionary statement.
Because these forward-looking statements are subject to a number of risks
and uncertainties, IntelGenx's actual results could differ materially
from those expressed or implied by these forward looking statements.
Factors that could cause or contribute to such differences include, but
are not limited to, those discussed under the heading "Risk Factors" in
IntelGenx's annual report on Form 10-K for the fiscal year ended December
31, 2008, filed with the United States Securities and Exchange Commission
and available at www.sec.gov, and also filed with Canadian securities
regulatory authorities and www.sedar.com. IntelGenx assumes no obligation
to update any such forward-looking statements.

Each of the TSX
Venture Exchange and OTC Bulletin Board has neither approved nor
disapproved the contents of this press release.

Contacts:
IntelGenx Technologies Corp.
Dr. Horst G. Zerbe
President and CEO
+1 514-331-7440 (ext. 201)
+1 514-331-0436 (FAX)
horst@intelgenx.com
www.intelgenx.com

Copyright 2009, Market Wire, All rights reserved.

-0-